Biopharma backer VenBio soars past Fund III target to reach $394m final close
Biopharma development investor VenBio Partners has soared past its target for its third life sciences fundraise to close
Sorry, you need to subscribe to read this article.
If you would like to access this article you must become a Premium Subscriber.
Premium subscribers receive complete access to our daily breaking news, premium stories, weekly Fundraising & IR Review, Knowledge Bank and LP profiles – all which are accessible via our mobile platform.
Subscribe below or contact Nadine Kudmany on +44 207 749 1289 or NKudmany@AltAssets.net